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Technical Report
Abstract
Purpose/ Background: To treat the cancerous tissues the unsealed radioisotopes are being in clinical practice since 7 decades.
From these unsealed sources, I-131 is the choice of treatment for the treating thyroid cancers. Orally administered I-131 pa-
tients are to be kept isolated in hospital for some period until captured activity in the body reaches to national and international
limits for the avoidance of unacceptably high radiation exposures to patients' family members and the general public to keep
ALARA (as low as reasonably achievable) principal in mind. The main rationale of this study was to calculate the exposure/dose
of the general public. Material and Methods: This work presents the exposure rate and dose to the general public in the corridor
and the non-radioactive patients admitted in adjacent room from I-131 administered isolated patients treated at NIMRA (Nu-
clear Institute of Medicine and Radiotherapy) Jamshoro Pakistan. In this study exposure from 23 thyroid cancer patients treated
with different activities of I-131 (50 to 200 mCi) from January 2011 to December 2012 were included. Results: The average ex-
posure rate in the corridor was about 5.17 µSv/hr (2.14 µSv/hr to 8.15 µSv/hr) and the cumulative dose to nonradioactive pa-
tients residing in an adjacent room was 0.647 mSv (0.192 mSv to 1.664 mSv). Conclusion: This study concludes that the expo-
sure rate to the general public especially the admitted non-radioactive patient in the adjacent room is almost within the limits
of 1 mSv as specified in national and international standards.
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Introduction
Radioiodine (I-131) is primarily β-emitting radionuclide
with 610 keV energy followed by a 364 keV photon.1-5 β ray
emitted from radioiodine contributes the major radiation
dose to the thyroid tissue and the gamma ray photon may
give rise the potential radiation hazard to others.1, 2 After
first usage of I-131 by Saul Hertz and Arthur Roberts in Jan-
uary 1941 6, it becomes an admired treatment option for
patients with thyroid cancer. Obliviously the Patients ad-
ministered I-131 therapeutic dosages are sources of undesir-
able high radiation exposure to close family members and
the general public.
Usually the patients are to be hospitalized until the exposure
rate from the patient’s body surface at one meter falls to ac-
ceptable levels of 1 mSv 7-9 according to national and inter-
national standard 9-11 and ALARA principal.12The main aim of
this study was to record and calculate the exposure rate/dose
to general public especially patients admitted in an adjacent
room at Nuclear Institute of Medicine and Radiotherapy
(NIMRA) Jamshoro Pakistan.
Methods and Materials
Exposure rate measurement is a key factor in radioiodine
administered patients. The aim of the measurement of expo-
sure rate is to maintain the radiation exposure/dose of the
general public as low as reasonably achievable.12, 13 If the
administered activity to the patient is more than 30 mCi,
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hospitalization of patient is necessarily in a special isolation
room is required until the achievement of captured activity
to less than 30 mCi or the drop off of exposure rate to less
than 50 Sv/hour.12, 14 Twenty three radioiodine adminis-
tered patients at NIMRA Jamshoro Pakistan with ages ranged
from 17 to 68 years and administered I-131 activities ranged
from 50 mCi to 200 mCi were included in this study. Pa-
tients' data such as age, sex, administered activity, date and
time of administration were recorded.15-17 Initial exposure
measurement for each of patient was recorded at the time of
administration of activity with twice daily exposure rate
measurement in corridor and adjacent room to isolation
room were noted with calibrated LAMSE RM1001-RD sur-
vey meter (Figure 1). The procedure was briefed to the each
patient and oral & written instructions regarding isolation of
patient were given to patient in order to keep the dose to
family members and general public minimum.9, 10, 16, 18-20, 26
The instructions were i) keeping the patient alone during
hospital stay in a special isolated room; ii) allowing caregiv-
ers/family members to present meals and water to the pa-
tient for very short periods; iii) ensuring plenty of liquids
intake; iv) chewing lemon/orange candies for minimizing
salivary glands’ dose; v) strongly advising lactating mothers
to stop breast feeding to their babies immediately to prevent
radioiodine ingestion through breast milk to the babies; vi)
recommending pregnancy avoidance for a period of 4 - 6
months after I-131 administration; vii) instructing the pa-
tients for maintaining safe distance between themselves and
their family members & general public, ensuring separate
arrangements of sleeping, avoiding public transport travel
and avoiding visit of public places such as shopping centers,
restaurants, theatres & public events; viii) for reduction of
dose to caregivers/close family members, patients and their
caregivers instructed for complying the same instructions at
home after discharge from hospital for one to two weeks as
maintained in isolation room.
FIG. 1: LAMSE RM1001-RD survey meter.
FIG. 2: Room setting of I-131 isolated and nonradioactive patients
with points of exposure rate/ dose measurements.
Figure 2 shows the room setting of I-131 isolated and nonra-
dioactive patients with points of exposure rate/dose meas-
urements. It was ensured that no same patient in adjacent
room received doses from the different patients. Every time
of isolation of I-131 administered patients, different patient
was admitted in adjacent room and there was no permanent
occupancy in corridor as it was used as passage/pathway in
the ward. The doses to nonradioactive patients in adjacent
room were calculated from the readings of survey meter and
the time duration of admission of I-131 isolated patients.
IAEA (International Atomic Energy Agency) mentioned in
its documents 21 that the majority of patients, excreted 50 -
60% of the administered activity in the first 24 hours and
different studies 2, 22 - 25 revealed that the percentage of
clearance of I-131 activity from patients is rapid (more than
80%) in first 48 hours whereas Driver and Packer 15 and
Memon SA et al. 26 reported that this clearance of magnitude
of (65 - 68) %. This indicated that the isolation period of
isolated patients in ward is short so the public dose may be
minor.
Results
The data of exposure rates in corridor and dose to patients
admitted in adjacent room is presented in Table 1. The rec-
orded average exposure rates from isolated patients in corri-
dor is ranged from 2.14 µSv/hr to 8.15 µSv/hr (average of
5.17 µSv/hr) and the cumulative doses to nonradioactive
patients admitted adjacent room as indicated in Table 1 is
ranges from 0.192 mSv to 1.664 mSv with an average of
0.647 mSv. 91% (n = 21) of patients in adjacent room re-
ceived less dose than allowable limit of 1 mSv 9-11 as shown
in Figure 3. Only 2 (9%) patients contribute some higher
doses to non-radioactive patients admitted in adjacent room
due to longer stay in isolation room than other patients.
The results of this study pointed out that the exposure to
family members of patients and the general public can be
minimized with i) sufficient radiation safety precautions and
measurements. ii) abiding the instructions by I-131 adminis-
tered patients.
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FIG. 3: Graphical representation of patient dose in adjacent room to I-131 isolated patient room with allowable limit (1 mSv) indication.










1 85 4.000 0.512
2 100 5.926 0.560
3 50 2.222 0.192
4 100 4.444 0.480
5 120 5.185 0.560
6 185 8.148 0.720
7 155 4.000 0.344
8 105 3.844 0.429
9 145 6.994 1.133
10 150 6.889 0.576
11 90 5.185 0.560
12 175 7.556 0.704
13 100 5.556 0.600
14 150 4.667 1.664
15 95 3.333 0.280
16 100 6.667 0.640

















22 160 2.135 0.341
23 100 2.828 0.632
Discussion
Along with family members/caregivers, the general pub-
lic/non-radioactive patient admitted in adjacent room are
also at risk from I-131 administered patients isolated in ward
but through proper radiation protection measurements it can
be effectively managed.27 The exposure rate/dose of the gen-
eral public from patients administered with I-131 during stay
at hospital needs some considerations. The comparison of
current study is not possible due to non-availability of data
on this study topic.
Although many studies 14, 17, 26, 28-34 have been conducted on
the dose to caregivers/family members of the patients as
summarized in Table 2 but no data was found for exposure
rate/dose to the general public from the I-131 therapeutic
patients. As Table 2 showed that the doses to caregiv-
ers/family members of the patients are within acceptable
limits, which pointed out that the dose to the general public,
will also be in the allowable limits and the patients treated
with radioiodine do not contribute a significant radiation
dose to the public.35
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TABLE 2: Different studies for dose to caregivers/family members of
I-131 administered patients.
Study Dose to caregivers/family members(mSv)
Grigsby et al. 14 0.01 to 1.09
Willegaignon et al. 17 < 1
Memon et al. 26 0.0321 to 0.235
AlMaskery and Bererhi 28 < 1
Rutar et al. 29 0.17 to 4.09
Tonnonchiang et al. 30 < 1
Marriott et al. 31 0.283
Sapienza MT et al. 32 < 1
Reiners and Lasmann 33 < 1
Cappelen et al. 34 < 1
The studies done by Thompson MA 2, Driver and Packer 15,
IAEA 21, Pacilio et al. 22, Tavakoli 23, Parthasarathy and
Crawford 24, Tuntawiroon et al. 25, and Memon SA et al. 26
reported that the most of activity cleared from patient in first
24 hours which confirmed that the public dose will not be
significant due to short isolation period of patients in ward.
Due to deficiency in research on the current topic, the com-
parison is impossible but the studies 2, 15, 21-26 vigorously sup-
ported the result of the current study.
Conclusion
The current study indicates that the exposure rate in corri-
dor is within acceptable limits and most of data for dose to
non-radioactive patients in adjacent room is also within tol-
erable limits. As there is no previous data available due to
lack of research on the current topic so authors suggest that
more studies may be conducted on subject to compare the
dose to the general public and for the authentication of cur-
rent study.
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